Since it is known that the synthesis of various microenvironmental proteins changes in MGUS, SMM, and MM, it is reasonable to assume that PACAP levels may vary over the course of progression from premalignant states to symptomatic disease, and that this peptide may represent an early predictor of disease progression. This evidence concerns the gene ADCYAP1 and Miyoshi myopathy.